News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Sees Chance Of U.S. Tresiba Launch Before Rival Products


3/21/2014 7:26:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday. In February 2013, U.S. regulators unexpectedly refused to approve Tresiba until the group conducted extra tests over potential heart risks, dealing a major blow to one of Novo Nordisk's key products as well as to its share price. "We judge that we still have an opportunity to launch Tresiba in the United States, if we are successful in the trials, before any significant competitive products are being entered into the market," Lars Rebien Sorensen told the company's annual general meeting.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES